ACAD Earnings Date: Nov 4, 2026 (Estimated) — Acadia Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ACAD's next earnings date?
Acadia Pharmaceuticals Inc. (ACAD) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.20 on revenue of $332.6M.
How did ACAD do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Acadia Pharmaceuticals Inc. posted EPS of $0.18 versus the $0.07 estimate, a beat of 350.0%. Revenue was $308.0M against a $296.6M estimate. The stock's 1-day post-earnings move was +6.1%.
How much does ACAD stock move after earnings?
ACAD beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.0% (up or down) in the day after earnings.
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 0.07 | 0.18 | +350.00% | $308.0M | ✅ Beat | +6.08% | +8.32% | +6.56% |
| 2026-05-06 | Q1 2026 | 0.07 | 0.02 | -71.43% | $268.1M | ❌ Miss | +5.03% | +3.26% | +0.37% |
| 2026-02-25 | Q4 2025 | 0.13 | 0.14 | +7.69% | $284.0M | ✅ Beat | -1.32% | -6.33% | -14.02% |
| 2025-11-05 | Q3 2025 | 0.14 | 0.26 | +85.71% | $278.6M | ✅ Beat | -3.05% | +8.06% | +22.88% |
| 2025-08-06 | Q2 2025 | 0.14 | 0.16 | +14.29% | $264.6M | ✅ Beat | +2.52% | +5.59% | +6.13% |
| 2025-02-26 | Q4 2024 | 0.23 | 0.08 | -65.22% | $259.6M | ❌ Miss | +1.79% | -4.84% | -9.53% |
| 2024-11-06 | Q3 2024 | 0.14 | 0.20 | +42.86% | $250.4M | ✅ Beat | +8.93% | +11.40% | +9.44% |
| 2024-08-06 | Q2 2024 | 0.19 | 0.20 | +5.26% | $242.0M | ✅ Beat | -19.52% | -16.55% | -13.95% |
Showing last 8 quarters.